Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
Karen Gelmon, Janice M Walshe, Reshma Mahtani, Anil A Joy, Meghan Karuturi, Patrick Neven, Dongrui Ray Lu, Sindy Kim, Patrick Schnell, Eustratios Bananis, Lee Schwartzberg, Karen Gelmon, Janice M Walshe, Reshma Mahtani, Anil A Joy, Meghan Karuturi, Patrick Neven, Dongrui Ray Lu, Sindy Kim, Patrick Schnell, Eustratios Bananis, Lee Schwartzberg
Abstract
Objective: In the PALOMA-2 trial, palbociclib in combination with letrozole prolonged progression-free survival (PFS) and exhibited an acceptable safety profile in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). This post hoc analysis of PALOMA-2 evaluated the efficacy and safety of palbociclib plus letrozole in patients with preexisting conditions grouped by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC).
Methods: Postmenopausal patients without prior treatment for ABC were randomized 2:1 to receive palbociclib (125 mg/d on a 3 weeks on/1 week off schedule) plus letrozole (2.5 mg/d, continuous) or placebo plus letrozole. Patients were grouped by the following MedDRA SOC preexisting conditions: gastrointestinal, musculoskeletal, metabolic, and vascular/cardiac. Median PFS was estimated by the Kaplan-Meier method, and treatment emergent adverse events (AEs) were compared between treatment arms within each preexisting condition subgroup.
Results: At baseline, 276 (41.4 %) patients had preexisting gastrointestinal disorders, 390 (58.6 %) had musculoskeletal disorders, 259 (38.9 %) had metabolic disorders, and 382 (57.4 %) had vascular/cardiac disorders. Baseline characteristics were similar between subgroups and between each arm within subgroups. Regardless of baseline preexisting condition, palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole. Treatment-emergent AEs associated with palbociclib plus letrozole and dose modifications due to AEs were similar across preexisting condition subgroups.
Conclusion: This post hoc analysis of PALOMA-2 demonstrated a favorable effect of palbociclib on PFS and a safety profile consistent with previous observations, regardless of underlying preexisting condition. Pfizer Inc (NCT01740427).
Keywords: Advanced breast cancer; Palbociclib; Preexisting condition; Progression-free survival; Safety.
Conflict of interest statement
Declaration of competing interest K Gelmon has received consulting/advisory fees from Pfizer Inc, Novartis, AstraZeneca, NanoString Technologies, and Merck. JM Walshe has received consulting/advisory fees and fees for non-CME services from Roche, Genomic Health, and Pfizer Inc. R Mahtani has received research funding from Agendia, Amgen, AstraZeneca, Biotheranostics, Daiichi, Eisai, Genentech, Immunomedics, Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, and SeaGen. AA Joy has received consulting/advisory fees from Mylan, Teva, Purdue, BMX, BI, Genomic Health, PUMA, Pfizer Inc, Roche, AstraZeneca, Novartis, and Lilly. M Karuturi has received consulting/advisory fees from Pfizer Inc. DR Lu, S Kim, P Schnell, and E Bananis are employees of and own stock in Pfizer Inc.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures
References
- Ording A.G., Garne J.P., Nystrom P.M., Froslev T., Sorensen H.T., Lash T.L. Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis–a Danish nationwide matched cohort study. PloS One. 2013;8:e76013.
- Sarfati D., Koczwara B., Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66:337–350.
- IBRANCE® capsules (palbociclib) Pfizer Inc; New York, NY: 2019. Full prescribing information.
- Rugo H.S., Finn R.S., Dieras V., Ettl J., Lipatov O., Joy A.A. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Canc Res Treat. 2019;174:719–729.
- Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936.
- Danese M.D., O'Malley C., Lindquist K., Gleeson M., Griffiths R.I. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol. 2012;23:1756–1765.
- Louwman W.J., Janssen-Heijnen M.L., Houterman S., Voogd A.C., van der Sangen M.J., Nieuwenhuijzen G.A. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Canc. 2005;41:779–785.
- Edwards M.J., Campbell I.D., Lawrenson R.A., Kuper-Hommel M.J. Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis. Breast Canc Res Treat. 2017;165:17–39.
- Sogaard M., Thomsen R.W., Bossen K.S., Sorensen H.T., Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5:3–29.
- Ettl J. Management of adverse events due to cyclin-dependent kinase 4/6 inhibitors. Breast Care (Basel) 2019;14:86–92.
- Rugo H.S., Turner N.C., Finn R.S., Joy A.A., Verma S., Harbeck N. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Canc. 2018;101:123–133.
- Muller L.M., Gorter K.J., Hak E., Goudzwaard W.L., Schellevis F.G., Hoepelman A.I. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–288.
- Finn R.S., Rugo H.S., Gelmon K.A., Cristofanilli M., Colleoni M., Loi S. Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5 years of follow-up. Oncologist. 2021;26:e749–e755.
Source: PubMed